TABLE 4.
Cruchaga et al., 10 polygenic risk score in participants homozygous for APOE ε3; demographics, age of onset, APOE, and polygenic risk score across diagnostic groups.
|
Diagnostic group (all APOE ε3/ε3 homozygotes) |
Age of symptom onset (years) | Age at first visit (years) | Sex, % female | Cruchaga et al., 10 PRS | PRS odds ratio (95% CI) predicting diagnostic group versus controls | PRS odds ratio (95% CI) predicting diagnostic group versus late‐onset AD |
|---|---|---|---|---|---|---|
|
Early‐onset AD ‐Entire group N = 77 |
55 (5.4) |
59 (5.5) |
49% |
0.0032 (0.0098) |
2.6 (1.2–6.0) |
1.5 (0.71–2.9) |
|
‐Multidomain N = 37 |
54 (5.0) | 58 (4.8) | 46% | 0.0019 (0.0091) | 2.9 (1.2–7.5) | 1.7 (0.71–3.9) |
|
‐Logopenic variant PPA N = 23 |
56 (6.2) | 61 (6.4) | 48% | 0.0075 (0.010) | 3.7 (1.1–13) | 1.6 (0.58–4.4) |
|
‐Posterior cortical atrophy N = 17 |
55 (5.2) | 59 (5.1) | 59% | 0.00068 (0.0098) | 1.7 (0.52–5.4) | 1.0 (0.34–3.2) |
|
Late‐onset AD N = 53 a |
77 (6.6) | 80 (7.3) | 58% | 0.0027 (0.086) | 1.7 (0.70–4.0) | N/A |
|
Controls N = 43 |
N/A | 69 (6.6) | 70% | −0.0013 (0.0097) | N/A | 0.59 (0.25–1.4) |
Note. Unless otherwise noted, all values are mean ± (standard deviation). Logistic regression co‐varies for sex.
Abbreviations: AD, Alzheimer's disease; APOE, apolipoprotein E; CI, confidence interval; PHS, polygenic hazard score; PPA, primary progressive aphasia; PRS, Cruchaga et al. polygenic risk score.
One late‐onset AD participant from the prior PHS group was not available at the time of data analysis (e.g., N = 53 instead of 54).